Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model

Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Controlled Release - Volume 217, 10 November 2015, Pages 160-169

Bonnie L. Hylander, Arindam Sen, Sarah H. Beachy, Rose Pitoniak, Soumya Ullas, John F. Gibbs, Jingxin Qiu, Joshua D. Prey, Gerald J. Fetterly, Elizabeth A. Repasky,